

Friday 14 March 2025

Request under Freedom of Information Act 2000

Thank you for your request for information which we received on Tuesday 25 February 2025. I am pleased to confirm the following.

Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with:

- Atezolizumab (Tecentriq)
- Durvalumab (Imfinzi)
- Nivolumab (Opdivo)
- Pembrolizumab (Keytruda)
- Chemotherapy
- Radiotherapy
- Chemotherapy AND Radiotherapy
- Osimertinib

Unable to provide this data.

Q2. How many patients were treated in the past 3 months for gastric cancer (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin)-0
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)-3
- Lonsurf (Trifluridine - tipiracil)-0
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)-1
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)-4
- Any other systemic anti-cancer therapy- Herceptin Capecitabine cisplatin = 2, FLOT 2
- Palliative care only- no access to this information
- Zolbetuximab (Vyloy)- 0

Q3 How many patients were treated in the past 3 months for cancer of the gastro-oesophageal junction (any stage) with:

- CAPOX (Capecitabine with Oxaliplatin)-0
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin)-0
- Lonsurf (Trifluridine - tipiracil)-0
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)-0

- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)-0
- Zolbetuximab (Vyloy)-0
- Any other systemic anti-cancer therapy -0
- Palliative care only -no access to this information

Q4 How many patients were treated in the last 3 months with any systemic anti-cancer therapies for Gastric cancer or cancer of the Gastro-Oesophageal Junction?

10

Q5. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma?

We do not treat melanoma in MKUH

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Team Lead
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the
'Re-use of Public Sector Information Regulations' and best practice.